Date de publication: 31 mars 2020
Promoteur – Intermédiaire Financier
AM-PHARMA HOLDING B.V.Lieu
Description
The Promoter is a Dutch biopharmaceutical company developing a proprietary enzyme that has the potential to transform the treatment prospects for patients with sepsis-induced conditions, such as Sepsis-Associated Acute Kidney Injuries (SA-AKI).
Objectifs
The proposed transaction will support R&D investments required to bring a product to the market addressing a high unmet medical need, in a growing patient population, preserving and cultivating highly skilled employment opportunities.
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 24 million
Coût total (montant approximatif)
EUR 49 million
Aspects environnementaux
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details will be verified during appraisal.
Passation des marchés
The promoter has been assessed by EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2014/24/EU), then the Bank would require the promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/24/EU and Directive 89/665/EEC), with publication of tender notices in the EU Official Journal, as and where required.
Statut
Signé - 19/12/2019
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).